Zymeworks (ZYME) Stock Price, News & Analysis

Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $13.48 to $14.12
• 50-Day Range: N/A
• 52-Week Range: $9.03 to $17.70
• Volume: 347,850 shs
• Average Volume: 533,686 shs
• Market Capitalization: $1.06 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Zymeworks Stock Analysis - MarketRank™

Zymeworks scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Zymeworks.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Zymeworks is -14.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zymeworks is -14.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zymeworks has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.32% of the float of Zymeworks has been sold short.

Short Interest Ratio / Days to Cover

Zymeworks has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Zymeworks has recently decreased by 0.87%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zymeworks does not currently pay a dividend.

Dividend Growth

Zymeworks does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.32% of the float of Zymeworks has been sold short.

Short Interest Ratio / Days to Cover

Zymeworks has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Zymeworks has recently decreased by 0.87%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.65

News Sentiment

Zymeworks has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.30 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Zymeworks this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Zymeworks to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zymeworks insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.92% of the stock of Zymeworks is held by insiders.

Percentage Held by Institutions

92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZYME Stock Analysis - Frequently Asked Questions

How have ZYME shares performed this year?

Zymeworks' stock was trading at $13.33 at the start of the year. Since then, ZYME stock has increased by 5.8% and is now trading at $14.10.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NASDAQ:ZYME) posted its quarterly earnings results on Thursday, August, 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.55. The company earned $48.73 million during the quarter, compared to analysts' expectations of $13.66 million. Zymeworks had a negative trailing twelve-month return on equity of 21.59% and a negative net margin of 59.96%.

When did Zymeworks IPO?

Zymeworks (ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZYME
• Previous Symbol: NASDAQ:ZYME
• CIK: 1937653
• Web: N/A
• Phone: (302) 274-8744
• Fax: 604-737-7077
• Employees: 460
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$122.69 million
• Net Margins: -59.96%
• Pretax Margin: -54.88%
• Return on Equity: -21.59%
• Return on Assets: -16.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.69
• Quick Ratio: 7.69

Sales & Book Value

• Annual Sales: $122.87 million
• Price / Sales: 8.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.92 per share
• Price / Book: 2.79

Miscellaneous

• Outstanding Shares: 75,166,000
• Free Float: 73,723,000
• Market Cap: $1.03 billion
• Optionable: N/A
• Beta: 1.26